Understanding differences in breast cancer outcomes for African American women
Subclonal heterogeneity and outcome disparities in Triple-Negative Breast Cancer among African Americans
This study is looking into why African American women are more likely to die from Triple-Negative Breast Cancer than Caucasian women, by examining the differences in their tumors to find better treatment options just for them.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11074040 on NIH RePORTER |
What this research studies
This research investigates why African American women experience higher mortality rates from Triple-Negative Breast Cancer (TNBC) compared to Caucasian women. It focuses on the biological differences in tumor characteristics, particularly looking at genetic mutations and subclonal heterogeneity, which may contribute to poorer treatment responses and survival rates. By analyzing tumor samples and gene expression profiles, the study aims to uncover the underlying mechanisms that lead to these disparities. The findings could help tailor more effective treatments for African American women with TNBC.
Who could benefit from this research
Good fit: Ideal candidates for this research are African American women diagnosed with Triple-Negative Breast Cancer.
Not a fit: Patients who do not have Triple-Negative Breast Cancer or are not African American women may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies and outcomes for African American women diagnosed with Triple-Negative Breast Cancer.
How similar studies have performed: Previous research has indicated significant biological differences in breast cancer outcomes among different racial groups, suggesting that this approach could yield valuable insights.
Where this research is happening
Boston, United States
- Massachusetts General Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Ellisen, Leif W — Massachusetts General Hospital
- Study coordinator: Ellisen, Leif W
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.